Marcela Tavares Luiz

Prof. Dr. Marcela Tavares Luiz


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MLMarcela Tavares Luiz
Marcela Tavares Luiz
JDJessyca Aparecida Paes Dutra
Jessyca Aparecida Paes Dutra
JVJuliana S Rosa Viegas
Juliana S Rosa Viegas
JAJennifer Thayanne Cavalcante de Araújo
Jennifer Thayanne Cavalcante de Araújo
Alberto Tavares JuniorAlberto Tavares Junior
Alberto Tavares Junior
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Cancer is one of the major public health problems worldwide. Despite the advances in cancer therapy, it remains a challenge due to the low specificity of treatment and the development of multidrug resistance mechanisms. To overcome these drawbacks, several drug delivery nanosystems have been investigated, among them, magnetic nanoparticles (MNP), especially superparamagnetic iron oxide nanoparticles (SPION), which have been applied for treating cancer. MNPs have the ability to be guided to the tumor microenvironment through an external applied magnetic field. Furthermore, in the presence of an alternating magnetic field (AMF) this nanocarrier can transform electromagnetic energy in heat (above 42 °C) through Néel and Brown relaxation, which makes it applicable for hyperthermia treatment. However, the low chemical and physical stability of MNPs makes their coating necessary. Thus, lipid-based nanoparticles, especially liposomes, have been used to encapsulate MNPs to improve their stability and enable their use as a cancer treatment. This review addresses the main features that make MNPs applicable for treating cancer and the most recent research in the nanomedicine field using hybrid magnetic lipid-based nanoparticles for this purpose.

24 November 2021 in Critical Reviews in Analytical Chemistry
Verified
Journal Article
Closed access
MLMarcela Tavares Luiz
Marcela Tavares Luiz
JDJessyca Aparecida Paes Dutra
Jessyca Aparecida Paes Dutra
LFLeonardo Delello Di Filippo
Leonardo Delello Di Filippo
Alberto Tavares JuniorAlberto Tavares Junior
Alberto Tavares Junior
LTLarissa Bueno Tofani
Larissa Bueno Tofani
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Epirubicin (EPI) is a chemotherapeutic agent belonging to the anthracycline drug class indicated for treating several tumors. It acts by suppressing the DNA and RNA synthesis by intercalating between their base pair. However, several side effects are associated with this therapy, including cardiotoxicity and myelosuppression. Therefore, EPI delivery in nanosystems has been an interesting strategy to overcome these limitations and improve the safety and efficacy of EPI. Thus, analytical methods have been used to understand and characterize these nanosystems, including spectrophotometric, spectrofluorimetric, and chromatography. Spectrophotometric and spectrofluorimetric methods have been used to quantify EPI in less complex matrices due to their efficiency, low cost, and green chemistry character. By contrast, high-performance liquid chromatography is a suitable method for detecting EPI in more complex matrices (e.g., plasm and urine) owing to its high sensitivity. This review summarizes physicochemical and pharmacokinetic properties of EPI, its application in drug delivery nanosystems, and the analytical methods employed in its quantification in different matrices, including blood, plasm, urine, and drug delivery nanosystems.

10 January 2023 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
JSJonas Corsino Maduro Soares
Jonas Corsino Maduro Soares
MLMarcela Tavares Luiz
Marcela Tavares Luiz
JJJoão Augusto Oshiro Junior
João Augusto Oshiro Junior
JBJoão Felipe Besegato
João Felipe Besegato
PMPriscila Borges Gobbo de Melo
Priscila Borges Gobbo de Melo
Marlus ChorilliMarlus Chorilli
Marlus Chorilli

23 December 2021 in Current Gene Therapy
Verified
Journal Article
Closed access
PDF file
MLMarcela Tavares Luiz
Marcela Tavares Luiz
LTLarissa Bueno Tofani
Larissa Bueno Tofani
VAVictor Hugo Sousa Araújo
Victor Hugo Sousa Araújo
LFLeonardo Delello Di Filippo
Leonardo Delello Di Filippo
JDJonatas Lobato Duarte
Jonatas Lobato Duarte
MCMarlus Chorilli
Marlus Chorilli
Gliomas are primary brain tumors originating from glial cells, representing 30% of all Central Nervous System (CNS) neoplasia. Among them, the astrocytoma grade IV (glioblastoma multiforme) is the most common, presenting an invasive and aggressive profile, with an estimated life expectancy of about 15 months after diagnosis even after treatment with radiation, surgical resection, and chemotherapy. This poor prognosis is related to the presence of the blood-brain barrier (BBB) and multidrug resistance mechanisms that prevent the uptake and retention of chemotherapeutics inside the brain. Gene therapy has been a promising strategy to overcome these treatment limitations since it has the ability to modify the defective genetic information in tumor cells, being able to induce cellular apoptosis and silence the genes responsible for multidrug resistance. Lipidbased nanoparticles, non-viral vectors, have been investigated to deliver genes across the BBB to reach the glioma cell target. Besides, their low immunogenicity, easy production, ability to incorporate ligands to specific target cells, and capacity to carry higher size genes have made the gene therapy based on non-viral vectors a promising glioma treatment. In this context, this review addresses the most common non-viral vectors based on lipid-based nanoparticles used for glioma gene therapy, such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and nanoemulsions.

24 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MLMarcela Tavares Luiz
Marcela Tavares Luiz
LFLeonardo Delello Di Filippo
Leonardo Delello Di Filippo
JDJessyca Aparecida Paes Dutra
Jessyca Aparecida Paes Dutra
JVJuliana S Rosa Viegas
Juliana S Rosa Viegas
ASAmanda Letícia Polli Silvestre
Amanda Letícia Polli Silvestre
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Dental caries is the most common oral disease, with high prevalence rates in adolescents and low-income and lower-middle-income countries. This disease originates from acid production by bacteria, leading to demineralization of the dental enamel and the formation of cavities. The treatment of caries remains a global challenge and the development of effective drug delivery systems is a potential strategy. In this context, different drug delivery systems have been investigated to remove oral biofilms and remineralize dental enamel. For a successful application of these systems, it is necessary that they remain adhered to the surfaces of the teeth to allow enough time for the removal of biofilms and enamel remineralization, thus, the use of mucoadhesive systems is highly encouraged. Among the systems used for this purpose, liquid crystalline systems, polymer-based nanoparticles, lipid-based nanoparticles, and inorganic nanoparticles have demonstrated great potential for preventing and treating dental caries through their own antimicrobial and remineralization properties or through delivering drugs. Therefore, the present review addresses the main drug delivery systems investigated in the treatment and prevention of dental caries.

1 October 2021 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
GRGiovanni Loureiro Raspantini
Giovanni Loureiro Raspantini
MLMarcela Tavares Luiz
Marcela Tavares Luiz
JAJuliana Palma Abriata
Juliana Palma Abriata
JEJosimar Eloy
Josimar Eloy
MVMiguel Menezes Vaidergorn
Miguel Menezes Vaidergorn
JMJuliana Maldonado Marchetti
Juliana Maldonado Marchetti